Robert Kemp

Junior Doctor at Southampton. Tweets my own. No FCOI.

[Robert Kemp @RSKemp01]

Once ask to define my goal in sentence - Prove what works, stop doing what doesn't, start doing what does. @BMj provides clear path

[Robert Kemp @RSKemp01]

@CharlesJiangMD You didn’t link the paper….

[Robert Kemp @RSKemp01]

@valhumphreys51 @DrLKVaughan Can I ask how this applies in say the legal profession. I assume you learn from anonymised cases? Do the individuals concerned have to consent to their cases being discussed and used for teaching?

[Jonathan @jabberwock951]

News for clinicians: if you access a patient record for reflective practice/education you're required to add a note explaining what you accessed and why.

Did anyone know this? Was it announced? Because it seems intended to catch people out.

https://t.co/oYWYbd7xDq

[Louella Vaughan @DrLKVaughan]

Just reading over the new rules on IG, as circulated in letter from Jim Mackey.

It is entirely appropriate to reiterate that patient records should be ONLY accessed for work-relate purposes. But the new rules are draconian and restrict the types of reasons doctors often do
1/

[Count Binface @CountBinface]

What’s that, @DaleVince? You want to give me an unconditional personal gift of £5million to do whatever I want with? Sure! I just need to fill out a form. If I didn’t declare it that would be silly.

[Rachel Reeves @RachelReevesMP]

I will accept Nigel Farage’s request to be appointed Steward and Bailiff of the Manor of Northstead.

It is a farce and a desperate distraction, and the people of Clacton deserve better.

But if he wants to spend the summer arguing with a bin, I won't stop him.

[The BMJ @bmj_latest]

The UK-US trade deal on pharmaceuticals more than doubles the amount of money the NHS will pay for new medicines over the next 11 years.

Diversion of NHS funds to pay for this will be detrimental to population health, argues Analysis in The BMJ
https://t.co/nmCH12wQ0y

[Anish Koka, MD @anish_koka]

And this isn’t a one off. It’s a pattern that follows biotechs with one drug they’re developing for a rare disease.

You can’t do large RCTs by definition in this group. The FDA understands that and accepts surrogates (as they should).. but this has become arbitrage for bad actors to get bad drugs on the market with bogus surrogates and the drugs have serious toxicities!

This is the playbook Sarepta has been running for a while with Duchennes, what Uniqure is trying to actively do with AMT-130, and what Capricor is doing with Deramiocel.

Resistance to obvious gaming by regulators .. leads to daily media stories about fda chaos and ultimately regulators being axed.

This is why @MartyMakary @VPrasadMDMPH @TracyBethHoeg aren’t at the FDA anymore.

Suddenly the media that didn’t cover the Chemocentryx NOOH letter or the avocapan retraction are very happy with the FDA.

“Stability returns”

Total Bullshit.

[Itai Yanai @ItaiYanai]

🔥 Published today, and just in time for summer conferences, here are your guidelines for presenting badly

[Luke Mordecai @Shr_Nottingham]

Watching loud tech bros going all in on full body scanning cos AI whilst doctors are like “we’ve all seen this movie before” is peak death of the expert stuff

Also always good to follow the money and medics ain’t selling anything here!

🤷‍♂️

[Adam C Palmer @ac_palmer]

Yikes, there is an oncologist on here posting AI hallucinations of survival data and calling it clinical trial results. Dangerously misleading to the public.

[Robert Kemp @RSKemp01]

@felix4better @oncology_bg Built in crossover with double blind randomisation could limit a lot of this.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Why not do a 1L trial that mandates crossover? If there is no crossover, then that’s what makes 1L RCT unethical. 1L RCT in itself is not unethical.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

🤦‍♂️

[Robert Kemp @RSKemp01]

@drsarahsam I’d want to know the context. Surrogacy is difficult to prove if we rarely measure it. In fact having an end point closer temporally to OS should in theory correlate better with OS.

I think it has a role in sequencing e.g. SONIA study

[Beth Nally @BethN01]

Thank you - this work was driven by conversations with patients who felt that conventional toxicity grading didn’t always capture the real impact of treatment on both daily life and long-term quality of life. Really pleased it has resonated!

[Robert Kemp @RSKemp01]

@AppleHelix @gtimblin I think ICI offers cures for a minority of melanoma patients. Possible same for NSCLC very high PDL1.

[Mark Lewis, MD, FASCO @marklewismd]

“X % of patients found the side effects acceptable” strikes me as far more authentic than “manageable toxicity”, and acknowledges who’s actually experiencing the AEs!

When the patient & oncologist meet, there are 2 experts in the room: one embodied & one necessarily removed

[Robert Kemp @RSKemp01]

@JCmacc1 @joe_fenrir @iskander @DrSamuelBHume Many many studies have involved a IV placebo. Several involved sham surgery. It is not unethical.

[Robert Kemp @RSKemp01]

@JCmacc1 @joe_fenrir @iskander @DrSamuelBHume Double dummy placebo. Everyone gets and IV and a pill. 50% have one active other placebo. 50% reverse. Not necessarily practically. But you can double blind that way.